Physician profile
Rodolfo Cepero
NPI 1023087921
$8,642.01
in general payments reported to CMS, 2019-2025
31 companies · $631 in 2025
The $631 reported for 2025 was more than what 82% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,231 · 2020: $1,832 · 2021: $1,875 · 2022: $831 · 2023: $774 · 2024: $467 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.57 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,987.68 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,395.29 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $1,289.10 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $705.86 | 2019-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $589.24 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $435.40 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $379.02 | 2020-2025 | |
| Astellas Pharma US INC | $352.03 | 2019-2023 | Myrbetriq |
| Janssen Pharmaceuticals, INC | $130.69 | 2019-2021 | |
| Acerus Pharmaceuticals Corporation | $124.99 | 2021 | |
| Akcea Therapeutics, INC. | $119.54 | 2019 | |
| Exactech, INC. | $109.93 | 2021 | |
| Bausch Health US, LLC | $106.58 | 2019-2020 | |
| Amarin Pharma, INC. | $96.48 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $93.31 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $90.47 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.29 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $82.56 | 2019-2020 | |
| Genentech USA, INC. | $80.13 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.45 | 2019-2020 | |
| Amgen INC. | $58.70 | 2019-2024 | Otezla, Repatha |
| Biogen, INC. | $48.01 | 2021 | |
| Glaxosmithkline, LLC. | $43.41 | 2020-2024 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $36.59 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $23.18 | 2019 | |
| Eisai INC. | $21.23 | 2020 | |
| Hikma Pharmaceuticals USA | $21.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.85 | 2019 | |
| Arbor Pharmaceuticals, INC. | $20.23 | 2021 | |
| Paratek Pharmaceuticals, INC. | $19.13 | 2024 | Nuzyra |
| Phadia US INC. | $16.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Cepero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.